Investor Presentaiton
Investor presentation
Full year 2018
Slide 31
North America Operations at a glance
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
50
Population with diabetes
Diabetes growth rate
NN Insulin MS
NN OAD MS
bDKK
400
NN GLP-1 MS
Full Year 2018
Sales
(mDKK)
Growth²
80%
Long-acting insulin³
12,902
(9%)
22%
40
40
220%
Premix insulin4
1,332
(22%)
GLP-1
300
60% Fast-acting insulin5
10,021
(4%)
39
39.0%¹
Human insulin
1,917
3%
30
32
200
+40%
Total insulin
26,172
(7%)
20
20
GLP-16
19,850
19%
17.1%¹
Insulin
Other diabetes care?
890
(1%)
100
20%
10
10
Diabetes care
46,911
2%
23.1%¹
OAD
Obesity (SaxendaⓇ)
2,658
39%
0
0%
Biopharm³
7,338
(6%)
2000
2017
2045
Nov
2013
Nov
2018
Total
56,908
5%
North America Population 2018: ~0.4 billion people and diabetes
prevalence ~11%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for 5-year period
Competitor value market share comparison for insulin as of Nov 2018:
Novo Nordisk 43%, Eli Lilly 31% and Sanofi 27%
Competitor value market share comparison for GLP-1 as of Nov 2018:
Novo Nordisk 45%, Eli Lilly 42% and AstraZeneca 12%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Nov, 2018 value figures
2 Percentage change in local currency from full year 2017 to full year
2018
3 Comprises Tresiba®, XultophyⓇ and Levemir®; 4 Comprises NovoMix®;
5 Comprises FiaspⓇ and NovoRapidⓇ; 6 Comprises VictozaⓇ and
Ozempic®; 7 Comprises Novo Norm® and needles; 8 Comprises primarily
NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, NorditropinⓇ,
Vagifem® and Activelle®View entire presentation